S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ABUS · Arbutus Biopharma Corporation
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Arbutus Biopharma Corp (ABUS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$4.17
-0.15
(-3.47%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.17
$4.17
$4.34
52-WEEK RANGE
$4.17
$3.50
$5.45
What's happening
- ABUS is down 3.47% today, trading at $4.17. — Live quote
- Volume today (143,680) is well below its 3-month average of 4,228,190. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.03 actual vs. $-0.02 estimated (-47.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ABUS
-12.06%
vs S&P 500
-24.46%
1-YEAR RETURN
ABUS
-4.08%
vs S&P 500
-19.45%
6-MONTH RETURN
ABUS
-5.58%
3-MONTH RETURN
ABUS
-4.08%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.03
Est. $-0.02
MISS -47.1%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.03
MISS -63.4%
2026-01-26 (Q4 2025)
$-0.02
Est. $-0.04
BEAT +44.0%
2025-10-26 (Q3 2025)
$-0.04
Est. $-0.03
MISS -26.6%
Valuation Measures & Ratios
Enterprise Value4$838.8M
Forward P/E534.10
PEG Ratio6—
Price / Sales (TTM1)4.70
Price / Book73.66
EV4 / Revenue4.62
EV4 / EBITDA5.63
Profit Margin84.23%
Operating Margin81.99%
Return on Equity (ROE8)90.98%
Return on Assets (ROA9)82.34%
Avg Volume (3M)4,228,190
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $822.9M | $875.8M | $880.7M | $777.1M | $658.4M |
| P/E | 5.16 | 6.26 | -17.80 | -12.63 | -8.04 |
| Price/Sales | 4.30 | 4.56 | 61.28 | 49.92 | 103.51 |
| Price/Book | 3.18 | 3.37 | 11.38 | 9.37 | 8.32 |
| EV/Revenue | 4.20 | 4.43 | 59.72 | 47.51 | 97.68 |
| EV/EBITDA | 5.16 | 6.25 | -16.01 | — | — |
| ROE | 61.58% | 53.79% | -63.91% | -74.14% | -103.48% |
| ROA | 58.15% | 50.49% | -50.62% | -59.57% | -70.01% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short34,053,358
Change from Prior Settlement+84.22%
% of Float—
Days to Cover (Short Ratio)3.53
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 84.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-07; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -90.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is -4.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ABUS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $179.1M | $529.0K | $10.7M | $1.8M | $1.3M | $1.7M | $1.5M |
| Operating income | -$6.0M | $168.9M | -$8.7M | $1.5M | -$25.7M | -$21.4M | -$21.6M | -$19.4M |
| Net income | -$5.1M | $169.7M | -$7.7M | $2.5M | -$24.5M | -$19.7M | -$19.8M | -$17.9M |
| EPS (diluted) | $-0.03 | $0.87 | $-0.04 | $0.01 | $-0.13 | $-0.10 | $-0.11 | $-0.10 |
| EPS (basic) | $-0.03 | $0.88 | $-0.04 | $0.01 | $-0.13 | $-0.10 | $-0.11 | $-0.10 |
| Operating margin | -$588 | $94 | -$1.6K | $14 | -$1.5K | -$1.6K | -$1.3K | -$1.3K |
| Net margin | -$507 | $95 | -$1.5K | $23 | -$1.4K | -$1.5K | -$1.1K | -$1.2K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $274.0M | $277.2M | $94.6M | $97.7M | $103.3M | $117.0M | $131.7M | $140.4M |
| Total liabilities | $15.3M | $17.0M | $18.0M | $20.3M | $20.3M | $37.9M | $34.3M | $33.6M |
| Stockholders' equity | $258.7M | $260.2M | $76.6M | $77.4M | $83.0M | $79.2M | $97.4M | $106.9M |
| Total current assets | $273.9M | $277.0M | $94.5M | $97.4M | $103.1M | $116.8M | $127.3M | $132.8M |
| Total current liabilities | $3.4M | $5.1M | $6.0M | $5.2M | $5.0M | $19.4M | $15.6M | $18.9M |
| Cash & equivalents | $19.2M | $23.7M | $18.0M | $22.4M | $37.4M | $37.1M | $36.3M | $31.8M |
| Marketable securities (current) | — | — | $73.5M | — | — | — | $86.3M | — |
| Accounts receivable | $369.0K | $1.3M | $1.4M | $905.0K | $1.0M | $1.2M | $2.4M | $1.6M |
| Marketable securities (non-current) | — | — | $0 | — | — | — | $0 | $3.0M |
| Property, plant & equipment | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3.3M | $3.6M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | — |
| Deferred revenue (current) | — | — | $0 | $0 | $0 | $6.8M | $7.6M | $10.9M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common stock & paid-in capital | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B |
| Retained earnings | -$1.22B | -$1.21B | -$1.38B | -$1.38B | -$1.37B | -$1.37B | -$1.35B | -$1.33B |
| Accumulated other comprehensive income (loss) | -$48.2M | -$48.2M | -$48.1M | -$48.1M | -$48.2M | -$48.2M | -$48.1M | -$48.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.0M | -$8.1M | -$4.7M | -$5.8M | -$15.7M | -$13.4M | -$10.3M | -$20.7M |
| Investing cash flow | -$1.7M | $2.2M | -$1.4M | -$10.0M | $15.6M | $11.3M | $13.4M | -$12.0M |
| Financing cash flow | $3.1M | $11.6M | $1.6M | $844.0K | $453.0K | $2.8M | $1.4M | $1.8M |
| Free cash flow | — | — | -$4.7M | -$5.8M | -$15.7M | -$13.4M | -$10.4M | -$20.7M |
| Capital expenditures | — | — | $0 | $0 | $0 | $0 | $86.0K | $0 |
| Depreciation & amortization | $11.0K | $11.0K | — | $11.0K | $11.0K | $330.0K | — | $336.0K |
| Share-based compensation | $1.6M | $1.4M | $1.3M | $1.3M | $864.0K | $3.6M | $1.6M | $2.2M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $82.0K | -$1.2M | $129.0K | -$120.0K | -$157.0K | -$1.2M | $801.0K | -$159.0K |
| Change in inventory | — | — | — | — | — | — | — | — |
| Purchases of investments | $23.7M | $13.8M | $25.5M | $51.3M | $28.5M | $34.7M | $43.2M | $40.3M |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M |
| EPS (diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| EPS (basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Operating margin | -$271 | -$1.2K | -$431 | -$168 | -$669 |
| Net margin | -$238 | -$1.1K | -$402 | -$178 | -$694 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
| Stockholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M |
| Total current assets | $94.5M | $127.3M | $132.0M | $151.1M | $160.7M |
| Total current liabilities | $6.0M | $15.6M | $22.5M | $32.9M | $11.2M |
| Cash & equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M |
| Marketable securities (current) | $73.5M | $86.3M | $99.7M | $116.1M | $46.0M |
| Accounts receivable | $1.4M | $2.4M | $1.8M | $1.4M | $899.0K |
| Marketable securities (non-current) | $0 | $0 | $6.3M | $37.4M | $35.7M |
| Property, plant & equipment | $32.0K | $3.3M | $4.7M | $5.1M | $6.0M |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K |
| Deferred revenue (current) | $0 | $7.6M | $11.8M | $16.5M | $0 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Common stock & paid-in capital | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B |
| Retained earnings | -$1.38B | -$1.35B | -$1.28B | -$1.20B | -$1.13B |
| Accumulated other comprehensive income (loss) | -$48.1M | -$48.1M | -$48.4M | -$50.5M | -$48.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Investing cash flow | $15.6M | $22.9M | $50.8M | -$74.9M | -$12.7M |
| Financing cash flow | $5.7M | $52.0M | $30.6M | $31.8M | $137.2M |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
| Capital expenditures | $0 | $182.0K | $1.0M | $512.0K | $809.0K |
| Share-based compensation | $7.0M | $9.0M | $9.3M | $7.2M | $6.4M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | -$1.4M | $633.0K | $424.0K | $453.0K | -$413.0K |
| Change in inventory | — | — | — | — | — |
| Purchases of investments | $140.1M | $141.5M | $80.5M | $130.4M | $82.2M |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ABUS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-04 to 2026-10-01
Recent transactions
- Most recent: Beardsley Robert A (Director) — Disposition to issuer of 17,948 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Beardsley Robert A | Director | Disposition to issuer | 2026-10-01 | 17,948 |
| Nguyen Tuan | Chief Financial Officer | Disposition to issuer | 2026-10-01 | 48,081 |
| Sawhney Roger | Director | Disposition to issuer | 2026-10-01 | 17,142 |
| Androski Lindsay | President and CEO | Disposition to issuer | 2026-10-01 | 24,655 |
| Roivant Sciences Ltd. | Reporting person | Disposition to issuer | 2026-10-01 | 8,967,383 |
| Naftzger J. Christopher | General Counsel and CCO | Grant / award | 2025-02-14 | 54,300 |
| McElhaugh Michael J. | Interim President & CEO | Grant / award | 2025-02-14 | 177,000 |
| HASTINGS DAVID C | Chief Financial Officer | Grant / award | 2025-02-14 | 90,100 |
| Sims Karen | Chief Medical Officer | Grant / award | 2025-02-14 | 49,300 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Beardsley Robert A | Director | Disposition to issuer | 17,948 | $5.00 |
| 2026-10-01 | Nguyen Tuan | Chief Financial Officer | Disposition to issuer | 48,081 | $5.00 |
| 2026-10-01 | Sawhney Roger | Director | Disposition to issuer | 17,142 | $5.00 |
| 2026-10-01 | Androski Lindsay | President and CEO | Disposition to issuer | 24,655 | $5.00 |
| 2026-10-01 | Roivant Sciences Ltd. | Reporting person | Disposition to issuer | 8,967,383 | $5.00 |
| 2026-09-18 | Androski Lindsay | President and CEO | Option exercise | 116,408 | $3.20 |
| 2026-09-18 | Androski Lindsay | President and CEO | Option exercise | 10,456 | $4.39 |
| 2026-09-18 | Androski Lindsay | President and CEO | Tax withholding | 82,527 | $5.07 |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Option exercise | 265,625 | $3.49 |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Option exercise | 27,475 | $4.39 |
| 2026-09-18 | Nguyen Tuan | Chief Financial Officer | Tax withholding | 206,637 | $5.07 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise | 52,533 | $3.34 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise | 78,800 | $4.24 |
| 2026-09-18 | Sawhney Roger | Director | Tax withholding | 100,508 | $5.07 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise | 52,533 | $3.20 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise | 78,800 | $4.24 |
| 2026-09-18 | Beardsley Robert A | Director | Tax withholding | 99,057 | $5.07 |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | Grant / award | 73,500 | $0.00 |
| 2026-02-02 | Androski Lindsay | President and CEO | Grant / award | 28,000 | $0.00 |
| 2025-02-14 | Naftzger J. Christopher | General Counsel and CCO | Grant / award | 54,300 | $0.00 |
| 2025-02-14 | McElhaugh Michael J. | Interim President & CEO | Grant / award | 177,000 | $0.00 |
| 2025-02-14 | HASTINGS DAVID C | Chief Financial Officer | Grant / award | 90,100 | $0.00 |
| 2025-02-14 | Sims Karen | Chief Medical Officer | Grant / award | 49,300 | $0.00 |
| 2025-02-04 | HASTINGS DAVID C | Chief Financial Officer | Open market sale | 22,183 | $3.28 |
| 2025-02-04 | Sims Karen | Chief Medical Officer | Open market sale | 19,348 | $3.28 |
| 2025-02-04 | McElhaugh Michael J. | Interim President & CEO | Open market sale | 23,790 | $3.28 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:51 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-07 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-21 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
Recent news
Headlines about ABUS (Arbutus Biopharma Corporation). Links open the publisher — we don’t host full articles.
-
Arbutus Biopharma (ABUS) Climbs 2.39% to $4.29, Nearing Key Resistance - SMA Signal
https://www.siam.in/ · 2026-10-16 -
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
SeekingAlpha · 2026-10-08 -
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Yahoo Finance · 2026-10-01 -
Arbutus gains on plans to buy back 46M shares in tender offer
Seeking Alpha · 2026-09-30 -
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Yahoo Finance · 2026-09-30 -
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Yahoo Finance · 2026-08-24 -
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
Yahoo Finance · 2026-08-21 -
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Yahoo Finance · 2026-08-21
No headlines in this category right now — try “All”.